CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the-1584G promoter polymorphism

被引：56

作者：

Gaedigk, A

Ryder, DL

Bradford, LD

Lceder, JS

机构：

[1] Childrens Mercy Hosp, Div Dev Pharmacol & Med Toxicol, Kansas City, MO 64108 USA

[2] Morehouse Sch Med, Dept Psychiat & Med, Atlanta, GA 30310 USA

来源：

CLINICAL CHEMISTRY | 2003年 / 49卷 / 06期

关键词：

D O I：

10.1373/49.6.1008

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

[No abstract available]

引用

页码：1008 / 1011

页数：4

共 13 条

[1]

*ALL NOM COMM, 2003, CYP2D6 ALL NOM

[2] In-vitro analysis of the contribution of CYP2D6.35 to ultrarapid metabolism [J].

Allorge, D ;

Harlow, J ;

Boulet, O ;

Hayhurst, GP ;

Chowdry, J ;

Roth, E ;

Crewe, K ;

Lo-Guidice, JM ;

Lhermitte, M ;

Broly, F ;

Tucker, GT ;

Ellis, SW .

PHARMACOGENETICS, 2001, 11 (08) :739-741

[3] Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans [J].

Gaedigk, A ;

Bradford, LD ;

Marcucci, KA ;

Leeder, JS .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (01) :76-89

[4] Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data [J].

Gaedigk, A ;

Gotschall, RR ;

Forbes, NS ;

Simon, SD ;

Kearns, GL ;

Leeder, JS .

PHARMACOGENETICS, 1999, 9 (06) :669-682

[5] Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population [J].

Griese, EU ;

Zanger, UM ;

Brudermanns, U ;

Gaedigk, A ;

Mikus, G ;

Morike, K ;

Stuven, T ;

Eichelbaum, M .

PHARMACOGENETICS, 1998, 8 (01) :15-26

[6] Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes [J].

Kubota, T ;

Yamaura, Y ;

Ohkawa, N ;

Hara, H ;

Chiba, K .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 50 (01) :31-34

[7] CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles [J].

Leathart, JBS ;

London, SJ ;

Steward, A ;

Adams, JD ;

Idle, JR ;

Daly, AK .

PHARMACOGENETICS, 1998, 8 (06) :529-541

[8] Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype:: a role for the CYP2D6*35 allele in ultrarapid metabolism? [J].

Lovlie, R ;

Daly, AK ;

Matre, GE ;

Molven, A ;

Steen, VM .

PHARMACOGENETICS, 2001, 11 (01) :45-55

[9] Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6 [J].

Raimundo, S ;

Fischer, R ;

Eichelbaum, M ;

Griese, EU ;

Schwab, M ;

Zanger, UM .

PHARMACOGENETICS, 2000, 10 (07) :577-581

[10] Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population [J].

Roh, HK ;

Dahl, ML ;

Johansson, I ;

IngelmanSundberg, M ;

Cha, YN ;

Bertilsson, L .

PHARMACOGENETICS, 1996, 6 (05) :441-447

← 1 2 →